Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMSAM Adhesion and Dermal Tolerability in Healthy Adults
NCT00531596Phase 4Completed
- Sponsor
- Somerset Pharma
- Start
- Apr 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of selegiline in major depressive disorder (MDD) (3 arms), sponsored by Somerset Pharma. Primary endpoints: Adhesion characteristics at 21 days and Dermal tolerability (irritation) at 21 days. Started Apr 2007; status: completed.
02
Drugs
selegiline
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00531596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00531596.